Key result
Inactivated BEA-FMDV vaccine achieves ~93% protection in mice and pigs without significant toxicity.
Why the study?
To develop a novel water-in-oil-in-water adjuvant and evaluate its effect on an inactivated foot-and-mouth disease vaccine.
Promising immunogenicity and protection in rodents and swine; leaves open field efficacy and strain coverage in commercial livestock.
To develop a novel water-in-oil-in-water (W/O/W) adjuvant and evaluate the effect on foot-and-mouth disease (FMD) inactivated vaccine, in this study, we prepared the novel nano-emulsion adjuvant based on QS-21 (BEA) which is composed of the mixture of mineral oil Marcol52, surfactant Tween80, oleate polyoxyethylene ether ester, polyoxyethylene palmitic acid ester and span80, cosurfactant polyethylene glycol and QS-21. The two-step emulsification method formed the W/O/W nano-emulsion with two films and three-phase structures. The effective particle diameter of the BEA was about 184 nm, and it has good thermal stability. Then, BEA was emulsified as an adjuvant to prepare for the inactivated FMDV vaccine, and BALB/c mice and pigs were immunized to evaluate its safety and immunization effect. The results showed that the inactivated BEA-FMDV vaccine significantly increased BALB/c mice and pigs' antibodies and cytokine IFN-γ in serum. Meanwhile, the pig-neutralizing antibodies were higher than control group. Safety tests found no symptoms of FMD or significant toxic reactions. After 28 days of immunization, the protection rate can reach 93.3%. The BEA vaccine had good stability at 4 °C, no stratification after 180 days, and the content of 146S in the vaccine did not decrease. In conclusion, the BEA prepared in this study is suitable for FMDV inactivated vaccine and is an effective adjuvant.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) studied Foot-and-mouth disease (FMD). Inactivated BEA-FMDV vaccine vs. Control group was evaluated on Protection rate after 28 days of immunization. The inactivated BEA-FMDV vaccine significantly increased antibodies and IFN-γ in mice and pigs, achieving a 93.3% protection rate after 28 days with no significant toxic reactions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: